Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock
Fundamentals
Source: third-party data provider, as of October 14, 2026
Compare with EPRX
Recent news

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
EPRX

New Strong Sell Stocks for April 2nd
New Strong Sell Stocks for April 2nd
EPRX
Technical indicators
- RSI 14
- 36.89
- MACD 12/26/9
- -0.12
- EMA 9 of MACD
- 0.06
- MACD histogram
- -0.18
- SMA 50
- $7.49
- Price below SMA 50
- EMA 50
- $7.53
- Price below EMA 50
- SMA 200
- $7.36
- Price below SMA 200
- EMA 200
- $7.22
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
EPRX

New Strong Sell Stocks for April 2nd
New Strong Sell Stocks for April 2nd
EPRX
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. James A. Helliwell FRCPC, M.D. | CEO & Director | 1974 |
| Mr. Alexander John Rothwell Eng., M.B.A. | Chief Financial Officer | 1969 |
| Mr. Paul Anthony Brennan B.Sc., M.Sc. | Chief Corporate Development Officer | — |
| Ms. Wajida Leclerc B.A., CCP, CHRP | Executive Vice President Corporate Services & People | 1960 |
| Mr. Alex Therien | Executive VP of R&D | — |
| Dr. Jeymi Tambiah M.S. | Chief Medical Officer | — |
| Dr. Jeffrey Millard Ph.d. | Executive Vice President of Technical Operations | 1976 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 14, 2026
Technical indicators
- RSI 14
- 36.89
- MACD 12/26/9
- -0.12
- EMA 9 of MACD
- 0.06
- MACD histogram
- -0.18
- SMA 50
- $7.49
- Price below SMA 50
- EMA 50
- $7.53
- Price below EMA 50
- SMA 200
- $7.36
- Price below SMA 200
- EMA 200
- $7.22
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $11.00
- Average
- $14.00
- High
- $17.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +43.5 | -14.7 |



